Herbimycin A, a tyrosine kinase inhibitor, impairs hypercalcemia associated with a human squamous cancer producing interleukin-6 in nude mice

Journal of Bone and Mineral Research

Volumn 11, Issue 7, 1996, Pages 905-911

  Moriyama, Keiji ^a,b   Williams, Paul J ^a   Niewolna, Maria ^a   Dallas, Mark R ^a   Uehara, Yoshimasa ^c   Mundy, Gregory R ^a   Yoneda, Toshiyuki ^a,d  

^a University of Texas Health Science Center   (United States)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HERBIMYCIN A; INTERLEUKIN 6; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYPERCALCEMIA; MOUSE; NONHUMAN; NUDE MOUSE; SQUAMOUS CELL CARCINOMA;

EID: 0029997042     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.5650110706     Document Type: Article

References (34)

1. Kishimoto T, Akira S, Taga T 1992 Interleukin-6 and its receptor: A paradigm for cytokines. Science 258:593-597.
2. Kishimoto T 1989 The biology of interleukin-6. Blood 71:1-10.
3. Bataille R, Klein B 1987 Autoimmune conditions induced by epithelial solid tumors. Rheumatol Int 7:231-233.
4. Kirnbauer R, Köck A, Schwartz T, Urbanski A, Krutmann J, Borth W, Damm D, Shipley G, Ansel JC, Luger TA 1989 IFN-β2, B cell differentiation factor 2, or hybridoma growth factor (IL-6) is expressed and released by human epidermal cells and epidermoid carcinoma cell lines. J Immunol 142:1922-1928.
5. Tabibzadeh SS, Poubouridis D, May LT, Sehgal PB 1989 Interleukin-6 immunoreactivity in human tumors. Am J Pathol 135:427-433.
6. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T 1989 Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250:607-610.
7. Takenawa J, Kaneko Y, Fukumoto M, Fukatsu A, Hirano T, Fukuyama H, Nakayama H, Fujita J, Yoshida O 1991 Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst 83:1668-1672.
8. Gallo O, Bani D, Toccofondi G, Almerigogna F, Storchi OF 1992 Characterization of a novel cell line from pleomorphic adenoma of the parotid gland with myoepithelial phenotype and producing interleukin-6 as an autocrine growth factor. Cancer 70:559-568.
9. Lu C, Vickers MF, Kerbel RS 1992 Interleukin-6: A fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA 89:9215-9219.
10. Takizawa H, Ohtoshi T, Ohta K, Yamashita N, Hirohata S, Hirai K, Hiramatsu K, Ito K 1993 Growth inhibition of human lung cancer cell lines by interleukin-6 in vivo: A possible role in tumor growth via an autocrine mechanism. Cancer Res 53:4175-4181.
11. Mule JJ, McIntosh JK, Jablons DM, Rosenberg SA 1990 Antitumor activity of recombinant interleukin-6 in mice. J Exp Med 171:629-636.
12. Porgador A, Tzehoval E, Katz A, Vadai E, Revel M, Feldman M, Eisenbach L 1992 Interleukin-6 gene transfection into Lervis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 52:3679-3686.
13. Mullen CA, Coale MM, Levy A, Stetler-Stevenson WG, Liotta LA, Brandt S, Blaese RM 1992 Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res 52:6020-6024.
14. Strassmann G, Fong M, Freter CE, Windsor S, D'Alessandro F, Nordin RP 1993 Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J Clin Invest 92:2152-2159.
15. Black K, Garrett IR, Mundy GR 1991 Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology 128:2657-2659.
16. Yoneda T, Nishikawa N, Nishimura R, Kato I, Sakuda M 1989 Three cases of oral squamous cancer associated with leukocytosis, hypercalcemia, or both. Oral Surg Oral Med Oral Pathol 68:604-611.
17. Yoneda T, Aufdemorte TB, Nishimura R, Nishikawa N, Sakuda M, Alsina MM, Chavez JB, Mundy GR 1991 Occurrence of hypercalcemia and leukocytosis with cachexia in a human squamous cell carcinoma of the maxilla in athymic nude mice: A novel experimental model of three concomitant paraneoplastic syndromes. J Clin Oncol 9:468-477.
18. Yoneda T, Nakai M, Moriyama K, Scott L, Ida N, Kunitomo T, Mundy GR 1993 Neutralizing antibodies to human interleukin-6 reverse hypercalcemia associated with a human squamous carcinoma. Cancer Res 53:737-740.
19. Ozanne B, Richards CS, Hendler F, Burns D, Gusterson B 1986 Overexpression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol 149:9-149.
20. Yoneda T, Alsina MM, Watanani K, Bellot F, Schlessinger J, Mundy GR 1991 Dependence of a human squamous carcinoma and associated paraneoplastic syndromes on the epidermal growth factor receptor pathway in nude mice. Cancer Res 51:2438-2443.
21. Uehara Y, Fukazawa H 1991 Use and selectivity of herbimycin A as inhibitor of protein-tyrosine kinase. Meth Enzymol 201:370-379.
22. Sambrook J, Fritsch EF, Maniatis T 1989 Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, U.S.A.
23. c-src expression during osteoclast formation in vitro. Mol Endocrinol 7:1313-1318.
24. Ida N, Sakurai S, Hosaka T, Hosoi H, Kunitomo T, Shimazu T, Maruyama T, Matsuura Y, Kohase M 1989 Establishment of strongly neutralizing monoclonal antibody to human interleukin-6 and its epitope analysis. Biochem Biophys Res Commun 165:728-734.
25. c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo. J Clin Invest 91:2791-2795.
26. Rose-John S, Heinrich PC 1994 Soluble receptors for cytokines and growth factors: Generation and biological function. Biochem J 300:281-290.
27. Ullrich A, Schlessinger J 1990 Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212.
28. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T, Kishimoto T, Suda T 1993 Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc Natl Acad Sci USA 90:11924-11928.
29. Mundy GR 1990 Calcium homeostasis. Hypercalcemia and hypocalcemia. Martin Dunitz Ltd., London, U.K.
30. Schobitz B, Pezeshki G, Pohl T, Hemann V, Heinrich PC, Holsboer F, Reul JMHM 1995 Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo. FASEB J 9:659-665.
31. 2 interferon/hepatocyte-stimulating factor/interleukin-6' promoter by cytokines, viruses and second messenger agonists. Proc Natl Acad Sci USA 85:6701-6705.
32. Wiley LM, Adamson ED, Tsark EC 1995 Epidermal growth factor receptor function in early mammalian development. BioEssays 17:839-846.
33. Ihre JN 1995 Cytokine receptor signalling. Nature 377:591-594.
34. Heldin C-H 1995 Dimerization of cell surface receptors in signal transduction. Cell 80:213-223.